Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2015

View Archived Issues

GlaxoSmithKline presents highlights of third quarter 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Vertex profiles pipeline progression in third quarter 2015

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Alexza to regain U.S. rights to Adasuve from Teva

Quark Pharmaceuticals plans new trials of QPI-1002

Q BioMed signs definitive license agreement for Mannin's platform technology assets

T-2762 shows efficacy for the treatment of dry eye syndrome

Sylentis identifies siRNA for treating allergic conjunctivitis

Significant activity seen with ustekinumab in Crohn's disease without TNF-antagonist resistance

XuanZhu Pharma patents EGFR inhibitors

Merck & Co. and Mochida develop FIXa inhibitors

University of California at Chapel Hill reports MerTK/TYRO3 inhibitors

Aileron Therapeutics discloses PTH1R antagonists

Kainos Medicine divulges Brd4 inhibitors

The Lung Cancer Research Foundation announces the award of 28 grants

Novel gene mutations associated with disease and developmental disorders reported at ASHG

Kite Pharma begins phase II ZUMA-1 trial

Glenmark and Genzyme report clinical results for vatelizumab in multiple sclerosis

Merck & Co. receives FDA breakthrough therapy designation for Keytruda in colorectal cancer

European approval for Eylea for the treatment of visual impairment due to myopic CNV

Novel biomarkers for gastrointestinal disorders discovered

SL-401 receives E.U. orphan drug designation for blastic plasmacytoid dendritic cell neoplasm

University of Oxford starts first-in-human study of prime-boost malaria vaccine

AGTC files IND application for the treatment of achromatopsia

Shire to acquire Dyax

BMS agrees to acquire Cardioxyl Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...